AZN - Ticker AI Digest

AstraZeneca PLC 📰 1
Desk Snapshot GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
AstraZeneca PLC in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, Today’s AI, and the deeper desks.
AZN Data 2025-11-06 Preview Mode
Core Deck
Deep Dive Modules

Digested News

Today's Catalysts (AZN) 1
AZN 06:01
AstraZeneca PLC
9M and Q3 2025 results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
## AstraZeneca 9M and Q3 2025 Results Summary
**Strong Performance and Pipeline Progress:**
AstraZenecas 9M and Q3 2025 results showcase continued strong commercial performance and significant pipeline advancements.
**Financial Highlights (9M 2025)**
* **Revenue Growth** Total revenue increased by 11% to $43.236 billion, driven by growth across all Therapy Areas, particularly Oncology (16%) and R&I (13%).
* **Core EPS Growth** Core EPS rose by 15% to $7.04, reflecting improved profitability.
* **Operating Profit Increase** Core operating profit grew by 13%, demonstrating operational efficiency.
**Pipeline Achievements**
* **16 Positive Phase III Readouts** AstraZeneca announced 16 positive Phase III trial results, including significant advancements in hypertension (baxdrostat), breast cancer (Enhertu, Datroway), and other areas.
* **31 Regulatory Approvals** The company secured 31 approvals in major regions for various medicines, expanding patient access.
* **Strong Oncology Pipeline** Oncology remains a key focus with 16 positive Phase III readouts and approvals for medicines like Enhertu, Datroway, and Imfinzi.
**Strategic Initiatives**
* **US Expansion** AstraZeneca is investing heavily in the US, including a $4.5 billion manufacturing facility in Virginia and a historic agreement with the US government to lower medicine costs.
* **Acquisition of SixPeaks Bio AG** This acquisition strengthens AstraZenecas position in weight management therapies.
* **Koselugo Agreement with Merck** A simplified agreement for Koselugo development and commercialization enhances focus and efficiency.
**Future Outlook**
* **Reiterated Guidance** AstraZeneca maintains its Total Revenue and Core EPS guidance for FY 2025, expecting high single-digit revenue growth and low double-digit Core EPS growth.
* **Sustainability Leadership** Recognized for sustainability efforts, AstraZeneca ranks highly in global sustainability rankings.
**Key Takeaways**
AstraZenecas 9M and Q3 2025 results demonstrate robust financial performance, significant pipeline progress, and strategic initiatives aimed at long-term growth. The companys focus on innovation, geographic expansion, and sustainability positions it well for continued success in the pharmaceutical industry.
Here is a comparison of AstraZeneca's financials and debt year on year, presented as an HTML table:
Metric9M 20259M 2024% ChangeQ3 2025Q3 2024% Change
Total Revenue$43,236m$39,182m10%$15,191m$13,565m12%
Reported EPS ($)$5.10$3.5743%$1.64$0.9277%
Core EPS ($)$7.04N/A15%$2.38N/A14%
Net Debt$23,965m$26,348m-9%N/AN/AN/A
Capital Expenditure$2,091m$1,415m48%N/AN/AN/A

Note: The above table provides a high-level comparison of key financials and debt metrics. For a detailed analysis, please refer to the original text.

Key Observations:

  • Total Revenue increased by 10% year-on-year in 9M 2025, driven by growth in all Therapy Areas.
  • Reported EPS increased significantly by 43% in 9M 2025, while Core EPS increased by 15%.
  • Net Debt decreased by 9% in the nine months to 30 September 2025, reflecting improved financial position.
  • Capital Expenditure increased by 48% in 9M 2025, primarily due to investment in manufacturing projects and technology upgrades.
This table provides a concise comparison of AstraZeneca's financials and debt year on year, highlighting key metrics such as Total Revenue, Reported EPS, Core EPS, Net Debt, and Capital Expenditure. The observations section summarizes the main trends and changes in these metrics.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 1
AZN 06:01
AstraZeneca PLC
Agreement with US Govt to lower medicine prices
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
Please provide the text you would like me to summarize. Im ready when you are!
Agreement
Approvals 2
AZN 06:01
AstraZeneca PLC
Koselugo (selumetinib) approved in the EU
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
AstraZenecas Koselugo (selumetinib) has been approved in the European Union (EU) for treating symptomatic, inoperable plexiform neurofibromas (PN) in adults with neurofibromatosis type 1 (NF1). The approval is based on positive results from the KOMET Phase III trial, which demonstrated a 20% objective response rate in tumor size reduction compared to 5% with placebo. This marks a significant advancement in addressing unmet needs for adult NF1 patients, as PN can cause severe symptoms like pain, disfigurement, and muscle weakness.
The KOMET trial, the largest and only placebo-controlled study in this population, enrolled 145 adults globally and confirmed Koselugos efficacy and safety profile, consistent with its established use in pediatric patients. Prof. Pierre Wolkenstein highlighted the trials robust findings, emphasizing the drugs ability to close treatment gaps for adults. Marc Dunoyer, CEO of Alexion (AstraZeneca Rare Disease), underscored the approvals importance in extending life-changing treatment options to adults with NF1 PN.
Koselugo, a selective MEK inhibitor, works by slowing tumor growth in NF1, a rare genetic condition affecting up to 50% of patients with PN. The drug has already been approved in Japan and other countries for adults and is approved in the US, EU, Japan, China, and elsewhere for pediatric NF1 patients. The collaboration between AstraZeneca and MSD further supports the development of Koselugo and other innovative treatments.
This approval reinforces AstraZeneca and Alexions commitment to advancing therapies for rare diseases, with Koselugo now available to adult NF1 patients across Europe.
Approvals
AZN 06:01
AstraZeneca PLC
Tezspire Approved in EU for CRSwNP
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZeneca and Amgens Tezspire (tezepelumab) has been approved in the European Union (EU) as an add-on therapy for adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who have not responded adequately to standard treatments. The approval is based on positive results from the WAYPOINT Phase III trial, which demonstrated significant reductions in nasal polyp severity, nasal congestion, and the need for surgery and systemic corticosteroids compared to placebo. This approval expands Tezspires use beyond severe asthma, highlighting its innovative mechanism targeting thymic stromal lymphopoietin (TSLP), a key driver of epithelial-driven inflammation. CRSwNP affects approximately 320 million people globally, with nearly half of European patients remaining uncontrolled despite current therapies. Tezspires safety profile in the trial was consistent with its known profile, with the most common adverse events being COVID-19, nasopharyngitis, and upper respiratory tract infection. The drug is also approved in the US for CRSwNP and severe asthma, with ongoing regulatory reviews in other countries and Phase III trials in COPD and eosinophilic esophagitis.
Approvals
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 1
AZN 06:06
AstraZeneca PLC
US FDA Approves Tezspire in CRSwNP
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
AstraZeneca and Amgens **Tezspire (tezepelumab)** has received **US FDA approval** for the **add-on maintenance treatment** of **chronic rhinosinusitis with nasal polyps (CRSwNP)** in adults and adolescents aged 12 and older. This approval expands Tezspires indication beyond severe asthma, marking it as the **first and only biologic targeting thymic stromal lymphopoietin (TSLP)** for CRSwNP. The decision was based on positive results from the **WAYPOINT Phase III trial**, which demonstrated significant reductions in nasal polyp severity, near-elimination of surgery needs, and decreased systemic corticosteroid use compared to placebo. CRSwNP affects approximately **320 million people globally**, causing persistent inflammation, nasal obstruction, and impaired quality of life. Tezspires approval offers a novel treatment option for patients with limited relief from current therapies. The drug is also under regulatory review in the **EU, China, Japan, and other countries** for CRSwNP, with ongoing Phase III trials exploring its use in **COPD and eosinophilic esophagitis (EoE)**. AstraZeneca and Amgen continue their collaboration, sharing costs and profits for Tezspires development and commercialization.
FDA
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
AZN 06:01
AstraZeneca PLC
9M and Q3 2025 results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
## AstraZeneca 9M and Q3 2025 Results Summary
**Strong Performance and Pipeline Progress:**
AstraZenecas 9M and Q3 2025 results showcase continued strong commercial performance and significant pipeline advancements.
**Financial Highlights (9M 2025)**
* **Revenue Growth** Total revenue increased by 11% to $43.236 billion, driven by growth across all Therapy Areas, particularly Oncology (16%) and R&I (13%).
* **Core EPS Growth** Core EPS rose by 15% to $7.04, reflecting improved profitability.
* **Operating Profit Increase** Core operating profit grew by 13%, demonstrating operational efficiency.
**Pipeline Achievements**
* **16 Positive Phase III Readouts** AstraZeneca announced 16 positive Phase III trial results, including significant advancements in hypertension (baxdrostat), breast cancer (Enhertu, Datroway), and other areas.
* **31 Regulatory Approvals** The company secured 31 approvals in major regions for various medicines, expanding patient access.
* **Strong Oncology Pipeline** Oncology remains a key focus with 16 positive Phase III readouts and approvals for medicines like Enhertu, Datroway, and Imfinzi.
**Strategic Initiatives**
* **US Expansion** AstraZeneca is investing heavily in the US, including a $4.5 billion manufacturing facility in Virginia and a historic agreement with the US government to lower medicine costs.
* **Acquisition of SixPeaks Bio AG** This acquisition strengthens AstraZenecas position in weight management therapies.
* **Koselugo Agreement with Merck** A simplified agreement for Koselugo development and commercialization enhances focus and efficiency.
**Future Outlook**
* **Reiterated Guidance** AstraZeneca maintains its Total Revenue and Core EPS guidance for FY 2025, expecting high single-digit revenue growth and low double-digit Core EPS growth.
* **Sustainability Leadership** Recognized for sustainability efforts, AstraZeneca ranks highly in global sustainability rankings.
**Key Takeaways**
AstraZenecas 9M and Q3 2025 results demonstrate robust financial performance, significant pipeline progress, and strategic initiatives aimed at long-term growth. The companys focus on innovation, geographic expansion, and sustainability positions it well for continued success in the pharmaceutical industry.
Here is a comparison of AstraZeneca's financials and debt year on year, presented as an HTML table:
Metric9M 20259M 2024% ChangeQ3 2025Q3 2024% Change
Total Revenue$43,236m$39,182m10%$15,191m$13,565m12%
Reported EPS ($)$5.10$3.5743%$1.64$0.9277%
Core EPS ($)$7.04N/A15%$2.38N/A14%
Net Debt$23,965m$26,348m-9%N/AN/AN/A
Capital Expenditure$2,091m$1,415m48%N/AN/AN/A

Note: The above table provides a high-level comparison of key financials and debt metrics. For a detailed analysis, please refer to the original text.

Key Observations:

  • Total Revenue increased by 10% year-on-year in 9M 2025, driven by growth in all Therapy Areas.
  • Reported EPS increased significantly by 43% in 9M 2025, while Core EPS increased by 15%.
  • Net Debt decreased by 9% in the nine months to 30 September 2025, reflecting improved financial position.
  • Capital Expenditure increased by 48% in 9M 2025, primarily due to investment in manufacturing projects and technology upgrades.
This table provides a concise comparison of AstraZeneca's financials and debt year on year, highlighting key metrics such as Total Revenue, Reported EPS, Core EPS, Net Debt, and Capital Expenditure. The observations section summarizes the main trends and changes in these metrics.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 10
AZN 06:01
AstraZeneca PLC
9M and Q3 2025 results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
## AstraZeneca 9M and Q3 2025 Results Summary
**Strong Performance and Pipeline Progress:**
AstraZenecas 9M and Q3 2025 results showcase continued strong commercial performance and significant pipeline advancements.
**Financial Highlights (9M 2025)**
* **Revenue Growth** Total revenue increased by 11% to $43.236 billion, driven by growth across all Therapy Areas, particularly Oncology (16%) and R&I (13%).
* **Core EPS Growth** Core EPS rose by 15% to $7.04, reflecting improved profitability.
* **Operating Profit Increase** Core operating profit grew by 13%, demonstrating operational efficiency.
**Pipeline Achievements**
* **16 Positive Phase III Readouts** AstraZeneca announced 16 positive Phase III trial results, including significant advancements in hypertension (baxdrostat), breast cancer (Enhertu, Datroway), and other areas.
* **31 Regulatory Approvals** The company secured 31 approvals in major regions for various medicines, expanding patient access.
* **Strong Oncology Pipeline** Oncology remains a key focus with 16 positive Phase III readouts and approvals for medicines like Enhertu, Datroway, and Imfinzi.
**Strategic Initiatives**
* **US Expansion** AstraZeneca is investing heavily in the US, including a $4.5 billion manufacturing facility in Virginia and a historic agreement with the US government to lower medicine costs.
* **Acquisition of SixPeaks Bio AG** This acquisition strengthens AstraZenecas position in weight management therapies.
* **Koselugo Agreement with Merck** A simplified agreement for Koselugo development and commercialization enhances focus and efficiency.
**Future Outlook**
* **Reiterated Guidance** AstraZeneca maintains its Total Revenue and Core EPS guidance for FY 2025, expecting high single-digit revenue growth and low double-digit Core EPS growth.
* **Sustainability Leadership** Recognized for sustainability efforts, AstraZeneca ranks highly in global sustainability rankings.
**Key Takeaways**
AstraZenecas 9M and Q3 2025 results demonstrate robust financial performance, significant pipeline progress, and strategic initiatives aimed at long-term growth. The companys focus on innovation, geographic expansion, and sustainability positions it well for continued success in the pharmaceutical industry.
Here is a comparison of AstraZeneca's financials and debt year on year, presented as an HTML table:
Metric9M 20259M 2024% ChangeQ3 2025Q3 2024% Change
Total Revenue$43,236m$39,182m10%$15,191m$13,565m12%
Reported EPS ($)$5.10$3.5743%$1.64$0.9277%
Core EPS ($)$7.04N/A15%$2.38N/A14%
Net Debt$23,965m$26,348m-9%N/AN/AN/A
Capital Expenditure$2,091m$1,415m48%N/AN/AN/A

Note: The above table provides a high-level comparison of key financials and debt metrics. For a detailed analysis, please refer to the original text.

Key Observations:

  • Total Revenue increased by 10% year-on-year in 9M 2025, driven by growth in all Therapy Areas.
  • Reported EPS increased significantly by 43% in 9M 2025, while Core EPS increased by 15%.
  • Net Debt decreased by 9% in the nine months to 30 September 2025, reflecting improved financial position.
  • Capital Expenditure increased by 48% in 9M 2025, primarily due to investment in manufacturing projects and technology upgrades.
This table provides a concise comparison of AstraZeneca's financials and debt year on year, highlighting key metrics such as Total Revenue, Reported EPS, Core EPS, Net Debt, and Capital Expenditure. The observations section summarizes the main trends and changes in these metrics.
AZN 15:01
AstraZeneca PLC
Result of General Meeting
AZN 14:01
AstraZeneca PLC
Total Voting Rights
AZN 06:06
AstraZeneca PLC
Director Declaration
AZN 06:01
AstraZeneca PLC
Koselugo (selumetinib) approved in the EU
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
AstraZenecas Koselugo (selumetinib) has been approved in the European Union (EU) for treating symptomatic, inoperable plexiform neurofibromas (PN) in adults with neurofibromatosis type 1 (NF1). The approval is based on positive results from the KOMET Phase III trial, which demonstrated a 20% objective response rate in tumor size reduction compared to 5% with placebo. This marks a significant advancement in addressing unmet needs for adult NF1 patients, as PN can cause severe symptoms like pain, disfigurement, and muscle weakness.
The KOMET trial, the largest and only placebo-controlled study in this population, enrolled 145 adults globally and confirmed Koselugos efficacy and safety profile, consistent with its established use in pediatric patients. Prof. Pierre Wolkenstein highlighted the trials robust findings, emphasizing the drugs ability to close treatment gaps for adults. Marc Dunoyer, CEO of Alexion (AstraZeneca Rare Disease), underscored the approvals importance in extending life-changing treatment options to adults with NF1 PN.
Koselugo, a selective MEK inhibitor, works by slowing tumor growth in NF1, a rare genetic condition affecting up to 50% of patients with PN. The drug has already been approved in Japan and other countries for adults and is approved in the US, EU, Japan, China, and elsewhere for pediatric NF1 patients. The collaboration between AstraZeneca and MSD further supports the development of Koselugo and other innovative treatments.
This approval reinforces AstraZeneca and Alexions commitment to advancing therapies for rare diseases, with Koselugo now available to adult NF1 patients across Europe.
Approvals
AZN 06:01
AstraZeneca PLC
Tezspire Approved in EU for CRSwNP
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZeneca and Amgens Tezspire (tezepelumab) has been approved in the European Union (EU) as an add-on therapy for adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who have not responded adequately to standard treatments. The approval is based on positive results from the WAYPOINT Phase III trial, which demonstrated significant reductions in nasal polyp severity, nasal congestion, and the need for surgery and systemic corticosteroids compared to placebo. This approval expands Tezspires use beyond severe asthma, highlighting its innovative mechanism targeting thymic stromal lymphopoietin (TSLP), a key driver of epithelial-driven inflammation. CRSwNP affects approximately 320 million people globally, with nearly half of European patients remaining uncontrolled despite current therapies. Tezspires safety profile in the trial was consistent with its known profile, with the most common adverse events being COVID-19, nasopharyngitis, and upper respiratory tract infection. The drug is also approved in the US for CRSwNP and severe asthma, with ongoing regulatory reviews in other countries and Phase III trials in COPD and eosinophilic esophagitis.
Approvals
AZN 06:06
AstraZeneca PLC
US FDA Approves Tezspire in CRSwNP
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
AstraZeneca and Amgens **Tezspire (tezepelumab)** has received **US FDA approval** for the **add-on maintenance treatment** of **chronic rhinosinusitis with nasal polyps (CRSwNP)** in adults and adolescents aged 12 and older. This approval expands Tezspires indication beyond severe asthma, marking it as the **first and only biologic targeting thymic stromal lymphopoietin (TSLP)** for CRSwNP. The decision was based on positive results from the **WAYPOINT Phase III trial**, which demonstrated significant reductions in nasal polyp severity, near-elimination of surgery needs, and decreased systemic corticosteroid use compared to placebo. CRSwNP affects approximately **320 million people globally**, causing persistent inflammation, nasal obstruction, and impaired quality of life. Tezspires approval offers a novel treatment option for patients with limited relief from current therapies. The drug is also under regulatory review in the **EU, China, Japan, and other countries** for CRSwNP, with ongoing Phase III trials exploring its use in **COPD and eosinophilic esophagitis (EoE)**. AstraZeneca and Amgen continue their collaboration, sharing costs and profits for Tezspires development and commercialization.
FDA
AZN 06:01
AstraZeneca PLC
Positive CHMP opinion for subcutaneous Saphnelo
AZN 06:01
AstraZeneca PLC
Agreement with US Govt to lower medicine prices
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
Please provide the text you would like me to summarize. Im ready when you are!
Agreement
AZN 06:01
AstraZeneca PLC
Baxdrostat met primary endpoint in Bax24 Ph3 trial

Today's AI

Today's AI Starts With News

1 live catalyst is opening Today’s AI for AZN.

Start with the live headline tape first. Today’s AI findings sit next, and the AI Blend stack drops lower once the news context is framed. Financial Forecastist now feeds the blend too.
Live Tape Data 2025-11-06 Blend Lower Down
Read the alert tape first, then open Today’s AI findings. Use AI Expand on any card to open the AI explanation, results tables and financial forecast rows instantly.
1 Today
Front Of Desk
AstraZeneca PLC has fresh news flow live now, so Today’s AI is leading with the tape before the blended signal stack below.
Single-Ticker Today's AI
AZN signal theatre built from scored market catalysts, automated AI forecasts, financial forecasting and live trigger logic.

This is the ticker-specific Today’s AI desk for AstraZeneca PLC. It compresses the live catalyst tape, bullish and bearish scoring, AI price forecasts, financial forecasting and trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI + Financial Blend Buy / Sell Trigger Engine Today's AI Findings
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full AZN Today’s AI cockpit.

Subscription turns this tab into a live signal desk with today’s news findings at the top, AI plus financial blend comparisons at the bottom, buy and sell trigger logic, and the full findings ledger behind every scored row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific Today’s AI stack, sentiment gauges, AI blend stage, and the full findings ledger for AZN on 2025-11-06.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
214.0B
Enterprise Value
188.0B
Public Float
99.4
Broker Target
16466.002
Shares Out
1.6B
Long Interest
100
Short Interest
0
Exchange
LSE
Currency Code
GBX
ISIN
GB0009895292
Market
LSE - MAIN MARKET
Sector
Health Care
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

1 live alert now opens the financials desk for AZN.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2025-11-06 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
1 Alerts
Front Of Desk
AstraZeneca PLC has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
2.36
Ex Divi
2026-02-19
Earnings Date
2026-02-05
Net Debt
23.9B
Cash
5.7B
EPS
4.94
Net Income
10.2B
Revenue
58.7B
Enterprise Value
188.0B
Trailing PE
27.9393
Forward PE
18.1159
Price Sales TTM
3.5416
Price Book MRQ
6.0377
EV Revenue
5.1626
EV EBITDA
15.4897
Financial Forecastist

Mixed financial engine

Revenue is accelerating +9.5% against the prior comparable period. Net margin is compressing by 1.3 pts. Net debt is building +1.1%.

Revenue +9.5% Net Income +2.8% FCF -44.5% Current Ratio 0.91x Forward Rev 16.2B
Mixed
Quarter Revenue
15.3B
+9.5%
vs prior comparable quarter
Net Margin
+20.1%
-1.3 pts
profitability pulse
Free Cash Flow
1.8B
-44.5%
cash conversion
Net Debt / EBITDA
4.6x
+1.1%
lower is cleaner
Revenue Engine

Latest quarter printed 15.3B with the top line pushing higher against the last comparable period.

Profit Stack

Net income landed at 3.1B and the margin profile is tightening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 7.6B while net debt is 26.4B. The leverage stack is moving the wrong way.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q3 2025
Consensus
14.8B
Revenue Path
2.27
EPS / Earnings
Growth cue +0.1%
Q1 2026
Consensus
14.9B
Revenue Path
2.52
EPS / Earnings
Growth cue +0.0%
Q2 2026
Consensus
15.4B
Revenue Path
2.50
EPS / Earnings
Growth cue +0.2%
Q3 2026
Consensus
16.2B
Revenue Path
2.69
EPS / Earnings
Growth cue +0.1%
FY 2026
Consensus
63.3B
Revenue Path
10.30
EPS / Earnings
Growth cue +0.1%
FY 2027
Consensus
67.1B
Revenue Path
11.62
EPS / Earnings
Growth cue +0.1%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q1 2026 15.3B 3.1B 1.8B 26.4B
Q4 2025 15.5B 2.3B 1.1B 23.9B
Q3 2025 15.2B 2.5B 4.4B 24.5B
Q2 2025 14.8B 2.5B 1.5B 25.8B
Q1 2025 14.0B 3.0B 3.3B 26.1B
Q4 2024 14.5B 1.5B 2.0B 24.6B

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2025 58.7B 10.2B 19.8B 8.7B
FY 2024 52.9B 6.9B 14.9B 7.3B
FY 2023 46.6B 6.1B 13.2B 6.6B
FY 2022 44.3B 3.3B 8.6B 7.2B
FY 2021 37.1B 109.9M 4.6B 3.8B

Structure DNA

Market Structure DNA

Yield Compounder profile with trend runway open

Price is 90.2% through the 52-week range, +2.2% vs 50DMA and +15.0% vs 200DMA. 57.3% of the register is locked by institutions and insiders, leaving 42.7% free float. Capital rhythm reads semi-annual with forward yield near 1.6% and payout around 25.8%.

Trend runway open Institutional gravity Reliable income rhythm As Of 2026-04-19
Yield Compounder
Structure Score
77.4 / 100
Yield Compounder
Trend Stack
+2.2% / +15.0%
vs 50DMA / 200DMA
52W Position
90.2%
auction position inside the yearly range
Ownership Lock
57.3%
57.3% institutions | 4.2% insiders
Pressure Pocket
42.7% free float
Vendor short-float fields were not supplied
Capital Rhythm
Semi-Annual
Yield 1.6% | payout 25.8%
Trend Runway

Implied spot is 15,118.00 with the stock +2.2% vs 50DMA and +15.0% vs 200DMA. The tape is sitting 90.2% through the 52-week range, which frames the regime as trend runway open.

Ownership Register

Institutions hold about 57.3% and insiders about 4.2%, locking roughly 57.3% of the register and leaving 42.7% in free float. That reads as institutional gravity.

Pressure Pocket

The API did not return a usable short-float field for this ticker, so the pressure score leans more on float lock and crowding than a full short ledger.

Capital Rhythm

Dividend cadence reads semi-annual with 2 event(s) in the last full year, a five-year average of 2.0, and stability score 100.0/100. Forward yield sits near 1.6% while payout is around 25.8%.

Structure Score

One-glance gauge for the current market-structure regime.

Pillar Radar

Trend, ownership, pressure, and capital rhythm mapped on one wheel.

Position And Float Balance

Shows whether the stock is extended, tightly held, or carrying capital-return support.

Dividend Cadence Tape

Historical dividend-event counts help reveal how dependable the income rhythm has been.

Dividend Cadence Ledger

Semi-Annual
Year Dividend Count Context
2026 1 Current partial year
2025 2 Full year
2024 2 Full year
2023 2 Full year
2022 2 Full year
2021 2 Full year
2020 2 Full year
2019 2 Full year

Structure Facts

Live Snapshot
Implied Spot
15,118.00
derived from market cap / shares
52W High
15,730.38
upper auction edge
52W Low
9,485.68
lower auction edge
Beta
0.28
volatility character
Shares Out
1.6B
fully diluted count
Shares Float
1.5B
tradable register
Shares Short
0
borrowed stock
Short Ratio
0.0x
days-to-cover style read
Ex-Dividend
2026-02-19
-59 day(s) to ex-date
Dividend Pay
-
payment date not supplied
Last Split
-
split date not supplied

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
4.9735
Institutions As Of
2025-12-04
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
5
Sale Director Dealing
2
Purchase TR1
3
Sale TR1
3
Broker Coverage Rows
40
Institution Holders Tracked
1
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for AZN, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2025-11-06 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
1 Today
Catalyst Pulse
AstraZeneca PLC has fresh news flow live now, so the tape is framing the chart workspace below.
AI Charts Studio
AZN Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-11-06 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
Desk Snapshot Member Login
Indicators0
Technicals0
AI Forecast 15.01%
RSI Gauge
Price Change
AI Forecast